

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Liver cancer	Cyclin dependent kinase 7 (CDK7); CDK9	<i>In vitro</i> and mouse studies identified a dual inhibitor of CDK7 and CDK9 that could help treat hepatocellular carcinoma (HCC). In cultured HCC cells, ibulocydine, a prodrug of a previously identified CDK inhibitor, blocked CDK7 and CDK9 to prevent cell growth better than the parent compound. In mice bearing HCC xenografts, ibulocydine inhibited tumor growth compared with vehicle control and did not cause toxicity compared with vehicle control. Next steps include complete preclinical evaluation of ibulocydine and its analogs.	Patent applications filed covering ibulocydine and its analogs; available for licensing	Cho, S.-J. <i>et al. J. Biol. Chem.</i> ; published online April 8, 2011; doi:10.1074/jbc.M110.209551 <b>Contact:</b> Seung-Ki Lee, Seoul National University, Seoul, South Korea e-mail: <a href="mailto:sklcrs@snu.ac.kr">sklcrs@snu.ac.kr</a>
		<b>SciBX 4(16); doi:10.1038/scibx.2011.456</b> Published online April 21, 2011		